Navigation Links
Recent Data Study Suggests Cortisol Could Help Alleviate Suffering for Those With Chronic Fatigue Syndrome and Fibromyalgia
Date:3/19/2008

New Hope Available for the Millions Suffering from these Diseases

LOS ANGELES, March 19 /PRNewswire-USNewswire/ -- Chronic fatigue syndrome (CFS) and fibromyalgia (FM) are two serious and debilitating diseases with no confirmed cause and limited treatment options. However, results of a new comprehensive literature study propose a simplified treatment process that could help alleviate symptoms for patients suffering from these diseases.

Kent Holtorf, M.D., medical director of the Holtorf Medical Group Center for Endocrine, Neurological and Infection Related Illness in Torrance, Calif., is advising a simplified treatment process that may help alleviate CFS and FM symptoms. From an extensive review of more than 50 published studies that assessed adrenal function in CFS and FM patients, Dr. Holtorf found that the majority of CFS and FM patients displayed abnormal adrenal function due to hypothalamic-pituitary dysfunction. The comprehensive review also showed that the majority of patients could be treated for this adrenal dysfunction. Dr. Holtorf's analysis, recently published in the Journal of Chronic Fatigue Syndrome, demonstrated that patients that were given cortisol as part of a multi-system treatment experienced significant improvement in their symptoms.

"My review of existing studies suggests that a treatment protocol of early administration of cortisol may help improve and reduce the symptoms of chronic fatigue syndrome and fibromyalgia," said Dr. Holtorf. "This research provides a new understanding that treating the known causes of illness in CFS and FM can improve the symptoms and quality-of-life of patients who suffer from these conditions."

CFS and FM primarily affect women in their 30s and 40s. According to the Centers for Disease Control and Prevention (CDC) more than one million Americans suffer from CFS while it is estimated that FM affects about 2 percent of the U.S. population. Unfortunately, both of these diseases are poorly understood by many physicians and there is no generally accepted test to accurately detect them. In addition, many CFS and FM patients express frustration because there is no clear treatment path for their conditions.

Dr. Holtorf's research was further confirmed in an observational study following the conditions of 500 patients from his clinic, where all of the patients were given cortisol as part of their treatment protocol:

-- 94 percent showed improvement by the fourth visit;

-- 75 percent noted significant improvement;

-- 62 percent reported substantial improvement; and

-- Energy levels and a general sense of well-being for patients doubled by the fourth visit.

The effectiveness of this multi-system treatment was further confirmed through the analysis of the cumulative findings of over 40 independent physicians and over 5,000 patients.

As shown in the Journal of Chronic Fatigue Syndrome study, cortisol doses of 5-to-15 mg a day have been shown to be safe, with little or no associated risk while having the potential for significant benefit for CFS and FM patients.

"Cortisol treatment carries significantly less risk and a greater potential for benefit than treatments considered to be the standard of care for both conditions," Dr. Holtorf explains.

What is Chronic Fatigue Syndrome?

Chronic fatigue syndrome, or CFS, is a debilitating and complex disease characterized by profound fatigue that is not improved by bed rest and that may be worsened by physical or mental activity. Persons with CFS most often function at a substantially lower level of activity than they were capable of before the onset of illness. In addition, patients report various symptoms, such as weakness, muscle pain, impaired memory and/or mental concentration, insomnia, and post-exertional fatigue lasting more than 24 hours. In some cases, CFS can persist for years. The cause or causes of CFS have not been identified and no specific diagnostic tests are available.

What is Fibromyalgia?

Fibromyalgia or FM is a chronic pain condition characterized by generalized muscular pain and fatigue. Fibromyalgia typically involves pain in the muscles, ligaments and tendons and related sleep and quality of life disturbances. This condition is often referred to as a "syndrome" because it is a set of signs and symptoms that occur together. The disease is often misunderstood because its symptoms are quite common; however, medical studies have proven that fibromyalgia does indeed exist.

Kent Holtorf, M.D.

Kent Holtorf, M.D. is an expert in the treatment of chronic fatigue syndrome, fibromyalgia, complex endocrine dysfunction and chronic infections (including EBV, HHV6 and Lyme disease). Dr. Holtorf received his doctorate of medicine from St. Louis University with residency training at UCLA. He has personally trained numerous physicians across the country to effectively treat chronic fatigue syndrome, fibromyalgia and chronic infectious diseases. Additionally, Dr. Holtorf was the founding medical director and developed the protocols for Fibromyalgia and Fatigue Centers and other centers across the country.

CONTACT: Julian Teixeira of Zeno Group, +1-202-965-7808


'/>"/>
SOURCE Zeno Group
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Alegent Health Sees Positive Results From Recent Clinician Usability Study Collaboration With Siemens and Motion Computing
2. Recent Studies Suggest Popular Diet Pill Relacore Reduces Acne Breakouts
3. Recent Findings from the Framingham Offspring Study Show Low Numbers of LDL Particles (LDL-P) by NMR are Associated With Fewer Heart Disease Related Events than Equivalently Low Levels of LDL Cholesterol (LDL-C).(1)
4. Studies Attribute Recent Increase in Multiple Myeloma Survival to Novel Therapies
5. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
6. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
7. Peptimmune Completes Phase I Study with a Novel Peptide Copolymer for the Treatment of Multiple Sclerosis
8. Study Compares Bronchodilatory Effects of SYMBICORT(R) and Advair in Adults With Asthma
9. NPS Reports Successful GATTEX(TM) Extension Study
10. NanoBio Corporation Successfully Completes Phase 2b Study in Herpes Labialis
11. deCODE Obesity Study Sheds Light on How Genetics Affects Risk and Onset of Common Diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... On Wednesday, March 22, ... at 5,821.64, up 0.48%; the Dow Jones Industrial ... and the S&P 500 closed at 2,348.45, slightly ... out of nine sectors ended the day in ... on the following Medical Instruments & Supplies equities: ...
(Date:3/23/2017)... 2017 Piramal Pharma ... gibt die Ernennung von Stuart E. Needleman ... globalen Pharmazeutikkunden eine einmalige integrierte End-to-End-Serviceplattform an ... für das erfolgreiche Wachstum und die Umsetzung ... Herr Needleman dafür verantwortlich sein, alle globalen ...
(Date:3/23/2017)... 23, 2017 Merrimack Pharmaceuticals, Inc. (NASDAQ: ... patient in a Phase 1 study of MM-310 in ... encapsulates a novel taxane and targets the EphA2 receptor, ... of many major tumor types, including prostate, ovarian, bladder, ... of this study is an important step in evaluating ...
Breaking Medicine Technology:
(Date:3/23/2017)... ... March 23, 2017 , ... The StayWell Company ... NCQA. The accreditation covers StayWell’s asthma, coronary artery disease, congestive heart failure, chronic ... organizations that have excellent programs for the delivery and improvement of disease management ...
(Date:3/23/2017)... , ... March 23, 2017 , ... ... families and businesses of the greater Fort Collins area, has unveiled a collaboration ... ongoing community involvement program. Donations to this worthy cause may now be made ...
(Date:3/23/2017)... ... , ... ?This conference will prominently feature 150+ Hospital and Health System Executive Speakers including: , ... , 43rd President of the United States of America: George W. Bush , ... Out of the Ring: Sugar Ray Leonard , JD, Chairperson, McGuireWoods LLP: Amber ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... improve all aspects of people’s health and nutrition, announced its product Leyzene is ... , Natural Subsistence develops nutritional supplements that help people improve all aspects of ...
(Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... The American ... 2017 marks the 40th Anniversary of ABQAURP’s dedication to Health Care Quality and Management ... who have contributed not only to the association, but also to the Health Care ...
Breaking Medicine News(10 mins):